| Title： | Chinese Expert Consensus on off-label Use of rheumatoid arthritis (2022 version) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (rheumatology, pharmacy, and other relevant fields) |
| Evidence classification method： | Relevant evidence on drug label, guidelines, consensuses, MICROMEDEX database, clinical studies are collected and evaluated. We evaluate the effectiveness grade, recommendation grade and evidence grade by referring to the Thomson classification system standard of Micromedex.In combination with evidence, experts of rheumatology, pharmacy are inquiried,and reach a consensus through the evaluation and optimization of the Delphi method. |
| Development unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| Registration time: | 2022-10-16 |
| Registration number： | PREPARE-2022CN654 |
| Purpose of the guideline: | In recent years, new drugs for the treatment of rheumatoid arthritis continue to be marketed, and new evidence-based medical evidence and updated domestic and foreign guidelines suggest that more drugs can be used for patients with rheumatoid arthritis in special periods such as pregnancy, pregnancy and lactation, but the update of drug instructions is relatively lagging behind.Therefore, it is necessary to form an expert consensus on the off-label use of rheumatoid arthritis, in order to provide a basis for clinicians to use off-label drugs in the treatment of rheumatoid arthritis, and to further standardize the clinical practice of off-label use of rheumatoid arthritis. |
Latest registration
